These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26836177)

  • 41. Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.
    Soejitno A; Tjan A; Purwata TE
    CNS Drugs; 2015 Jun; 29(6):487-502. PubMed ID: 26187557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm.
    Fulop T; Lacombe G; Cunnane S; Le Page A; Dupuis G; Frost EH; Bourgade-Navarro K; Goldeck D; Larbi A; Pawelec G
    Discov Med; 2013 Jan; 15(80):33-42. PubMed ID: 23375012
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on Prevention Trials in Alzheimer's Disease.
    Vellas B
    J Prev Alzheimers Dis; 2014; 1(3):168-175. PubMed ID: 29251744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genentech's Alzheimer's antibody trial to study disease prevention.
    Garber K
    Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
    [No Abstract]   [Full Text] [Related]  

  • 45. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials.
    Yaffe K; Tocco M; Petersen RC; Sigler C; Burns LC; Cornelius C; Khachaturian AS; Irizarry MC; Carrillo MC
    Alzheimers Dement; 2012 May; 8(3):237-42. PubMed ID: 22546356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial.
    Di Stefano F; Epelbaum S; Coley N; Cantet C; Ousset PJ; Hampel H; Bakardjian H; Lista S; Vellas B; Dubois B; Andrieu S;
    J Alzheimers Dis; 2015; 48(3):793-804. PubMed ID: 26402073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers in preclinical Alzheimer's disease.
    Chong MS; Lim WS; Sahadevan S
    Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 1: clinical and historical background.
    Fulop T; Lacombe G; Cunnane S; Le Page A; Dupuis G; Frost EH; Bourgade-Navarro K; Goldeck D; Larbi A; Pawelec G
    Discov Med; 2013 Jan; 15(80):23-32. PubMed ID: 23375011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarkers for Alzheimer's disease therapeutic trials.
    Hampel H; Wilcock G; Andrieu S; Aisen P; Blennow K; Broich K; Carrillo M; Fox NC; Frisoni GB; Isaac M; Lovestone S; Nordberg A; Prvulovic D; Sampaio C; Scheltens P; Weiner M; Winblad B; Coley N; Vellas B;
    Prog Neurobiol; 2011 Dec; 95(4):579-93. PubMed ID: 21130138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel disease-modifying therapies for Alzheimer's disease.
    Jiang T; Yu JT; Tan L
    J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.
    Scheinin NM; Scheinin M; Rinne JO
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):265-79. PubMed ID: 21532540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances and challenges in the prevention and treatment of Alzheimer's disease.
    Diaz Brinton R; Yamazaki RS
    Pharm Res; 1998 Mar; 15(3):386-98. PubMed ID: 9563067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recruitment methods for United States Alzheimer disease prevention trials.
    Schneider LS
    J Nutr Health Aging; 2012 Apr; 16(4):331-5. PubMed ID: 22499452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lost in Translation? Finding Our Way To Effective Alzheimer's Disease Therapies.
    Quinn JF
    J Alzheimers Dis; 2018; 64(s1):S33-S39. PubMed ID: 29758942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Current Landscape of Prevention Trials in Dementia.
    Lee J; Howard RS; Schneider LS
    Neurotherapeutics; 2022 Jan; 19(1):228-247. PubMed ID: 35587314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological strategies for the prevention of Alzheimer's disease.
    Doraiswamy PM; Xiong GL
    Expert Opin Pharmacother; 2006 Jan; 7(1):1-10. PubMed ID: 16370917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Research Investigating Alzheimer's Disease in China: Current Status and Future Perspectives Toward Prevention.
    Wang Q; Gao F; Dai LN; Zhang J; Bi D; Shen Y
    J Prev Alzheimers Dis; 2022; 9(3):532-541. PubMed ID: 35841254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach.
    Schelke MW; Hackett K; Chen JL; Shih C; Shum J; Montgomery ME; Chiang GC; Berkowitz C; Seifan A; Krikorian R; Isaacson RS
    Ann N Y Acad Sci; 2016 Mar; 1367(1):50-6. PubMed ID: 27116241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.